ALPHA2 ADRENERGIC RECEPTOR DYSFUNCTION IN PATIENTS W/ REGIONAL LIPOAT

区域 LIPOAT 患者的 ALPHA2 肾上腺素能受体功能障碍

• 批准号: 6264367
• 负责人: CHARLES A STUART
• 金额: $ 3.42万
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264367
• 关键词: adrenergic receptor; clinical research; human subject; lipodystrophy; medical complication

Partial or total lipoatrophy is characterized by insulin resistant diabetes, hypertiglyceridemia, fatty infiltration of the liver, and hypertension. The etiology of this syndrome is unknown. The alpha2 adrenergic receptor is a Gi-dependent system which normally antagonizes the lipolytic effects of beta adrenergic agonists primarily in peripheral fat depots and antagonizes alpha1.

部分或全部脂肪萎缩的特征在于胰岛素抵抗性糖尿病、高甘油三酯血症、肝脏脂肪浸润和高血压。 这种综合征的病因尚不清楚。 α 2肾上腺素能受体是一种Gi依赖性系统，通常主要在外周脂肪库中拮抗β肾上腺素能激动剂的脂解作用，并拮抗α 1。